Paul Choi
Stock Analyst at Goldman Sachs
(4.49)
# 1,115
Out of 5,116 analysts
382
Total ratings
55.6%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Reiterated: Buy | $90 → $101 | $88.34 | +14.33% | 21 | Oct 27, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $90 → $80 | $30.14 | +165.43% | 5 | Oct 22, 2026 | |
| RGNX REGENXBIO | Reiterated: Hold | $10 | $7.38 | +35.50% | 13 | Oct 20, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Hold | $36 | $38.87 | -7.38% | 6 | Sep 22, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $75 | $37.68 | +99.04% | 13 | Sep 17, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $105 | $55.55 | +89.02% | 12 | Aug 28, 2026 | |
| HR Healthcare Realty Trust | Reiterated: Hold | $14 | $19.07 | -26.59% | 1 | Aug 16, 2026 | |
| EXEL Exelixis | Reiterated: Buy | $64 | $68.71 | -6.85% | 10 | Aug 5, 2026 | |
| URGN UroGen Pharma | Reiterated: Hold | $44 → $48 | $25.73 | +86.55% | 25 | Aug 5, 2026 | |
| PTCT PTC Therapeutics | Reiterated: Sell | $55 → $70 | $65.67 | +6.59% | 26 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $300 | $253.45 | +18.37% | 27 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $19 → $14 | $14.20 | -1.41% | 20 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $9.73 | +311.10% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $6 | $6.55 | -8.40% | 8 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $112 → $116 | $74.27 | +56.19% | 35 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $77 → $94 | $100.70 | -6.65% | 5 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $11.02 | +90.56% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.08 | - | 18 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 | $11.58 | +3.67% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $40 | $9.42 | +324.63% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.92 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.66 | n/a | 25 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.28 | n/a | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $56.12 | n/a | 1 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $133.39 | $23.04 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.91 | n/a | 5 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $3.5 | $2.65 | n/a | 4 | Apr 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $7 | $9.77 | n/a | 8 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $9 | $14.73 | n/a | 5 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $17 | $83.01 | n/a | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $5.30 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $22,005.00 | n/a | 2 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 | $159.76 | n/a | 4 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $18 → $20 | $36.15 | n/a | 5 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $135 → $165 | $118.01 | n/a | 2 | Nov 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $1,364.73 | n/a | 1 | Apr 7, 2017 |
Kiniksa Pharmaceuticals International,
Oct 27, 2026
Reiterated: Buy
Price Target: $90 → $101
Current: $88.34
Upside: +14.33%
Vera Therapeutics
Oct 22, 2026
Reiterated: Buy
Price Target: $90 → $80
Current: $30.14
Upside: +165.43%
REGENXBIO
Oct 20, 2026
Reiterated: Hold
Price Target: $10
Current: $7.38
Upside: +35.50%
Edgewise Therapeutics
Sep 22, 2026
Reiterated: Hold
Price Target: $36
Current: $38.87
Upside: -7.38%
Xenon Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $75
Current: $37.68
Upside: +99.04%
Cytokinetics
Aug 28, 2026
Reiterated: Buy
Price Target: $105
Current: $55.55
Upside: +89.02%
Healthcare Realty Trust
Aug 16, 2026
Reiterated: Hold
Price Target: $14
Current: $19.07
Upside: -26.59%
Exelixis
Aug 5, 2026
Reiterated: Buy
Price Target: $64
Current: $68.71
Upside: -6.85%
UroGen Pharma
Aug 5, 2026
Reiterated: Hold
Price Target: $44 → $48
Current: $25.73
Upside: +86.55%
PTC Therapeutics
Jul 30, 2026
Reiterated: Sell
Price Target: $55 → $70
Current: $65.67
Upside: +6.59%
Jul 27, 2026
Reiterated: Buy
Price Target: $300
Current: $253.45
Upside: +18.37%
Jul 23, 2026
Rated: Hold
Price Target: $19 → $14
Current: $14.20
Upside: -1.41%
May 14, 2026
Reiterated: Buy
Price Target: $40
Current: $9.73
Upside: +311.10%
May 12, 2026
Reiterated: Sell
Price Target: $6
Current: $6.55
Upside: -8.40%
May 8, 2026
Reiterated: Buy
Price Target: $112 → $116
Current: $74.27
Upside: +56.19%
May 7, 2026
Reiterated: Hold
Price Target: $77 → $94
Current: $100.70
Upside: -6.65%
May 6, 2026
Reiterated: Buy
Price Target: $21
Current: $11.02
Upside: +90.56%
Apr 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $5.08
Upside: -
Feb 25, 2026
Reiterated: Sell
Price Target: $12
Current: $11.58
Upside: +3.67%
Feb 24, 2026
Downgraded: Hold
Price Target: $8 → $40
Current: $9.42
Upside: +324.63%
Feb 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $2.92
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $3.66
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.28
Upside: n/a
Jun 4, 2024
Reiterated: Buy
Price Target: n/a
Current: $56.12
Upside: n/a
Nov 10, 2023
Reiterated: Hold
Price Target: $133.39
Current: $23.04
Upside: n/a
Jun 28, 2023
Reiterated: Buy
Price Target: $19
Current: $1.91
Upside: n/a
Apr 3, 2022
Downgraded: Hold
Price Target: $25 → $3.5
Current: $2.65
Upside: n/a
Nov 5, 2021
Reiterated: Hold
Price Target: $8 → $7
Current: $9.77
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: $12 → $9
Current: $14.73
Upside: n/a
Mar 4, 2021
Reiterated: Buy
Price Target: $15 → $17
Current: $83.01
Upside: n/a
Nov 9, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $5.30
Upside: n/a
Aug 24, 2020
Reiterated: Sell
Price Target: n/a
Current: $22,005.00
Upside: n/a
Jun 29, 2020
Downgraded: Hold
Price Target: $135
Current: $159.76
Upside: n/a
Mar 30, 2020
Upgraded: Hold
Price Target: $18 → $20
Current: $36.15
Upside: n/a
Nov 1, 2017
Reiterated: Buy
Price Target: $135 → $165
Current: $118.01
Upside: n/a
Apr 7, 2017
Reiterated: Buy
Price Target: $90
Current: $1,364.73
Upside: n/a